New Biochip-based Blood Test Detects Elevated Risk for Alzheimer's Disease
Researchers at AACC Annual Scientific Meeting show test performs with same accuracy as gold standard DNA test
Researcher today unveiled results from a new blood test to help identify which patients are at an elevated risk of Alzheimer’s disease. The findings, presented at the 68th AACC Annual Scientific Meeting & Clinical Lab expo in Philadelphia, showed that the biochip test, which allows multiple tests to be run on one blood sample, was as accurate as existing molecular tests that analyze DNA. “This is the first time that we have used this biochip technology to test for an increased risk of Alzheimer’s disease,” said Emma C. Harte, PhD, a research scientist at Randox Laboratories. “This type of testing is important in our quest to undestand and diagnose Alzheimer’s and empower patients to understand risks, consider medication and even make early lifestyle changes.” To read more, click here.
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
2017 Managing Coding and Reimbursement Challenges
Aug. 17-19, 2017; Chicago
2017 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 30-Sept. 2, 2017; Chicago
Mayo Clinic Neuroscience and Oncology Innovation Summit 2017
Sept. 7-9, 2017; Orlando, Fla.
63rd Annual Meeting of the Western Neurological Society
Sept. 8-11, 2017; Banff, Alberta, Canada